Inhibitor Therapeutics (INTI) Return on Capital Employed Growth (3y) (2016 - 2026)
Inhibitor Therapeutics (INTI) Return on Capital Employed Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -356.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -516.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -4,078.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4,967.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5,777.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,445.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 109.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 513.00 |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -37,390.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,629.00 |
| Dec 31, 2025 | -15,427.00 |
| Sep 30, 2025 | -13,008.00 |
| Jun 30, 2025 | -11,949.00 |
| Mar 31, 2025 | -10,367.00 |
| Dec 31, 2024 | -12,207.00 |
| Sep 30, 2024 | -12,489.00 |
| Jun 30, 2024 | -18,658.00 |
| Mar 31, 2024 | -32,581.00 |
| Dec 31, 2023 | -38,374.00 |
| Sep 30, 2023 | -57,615.00 |
| Jun 30, 2023 | -132,421.00 |
| Mar 31, 2023 | 76,298.00 |
| Dec 31, 2022 | 34,886.00 |
| Sep 30, 2022 | 26,278.00 |
| Jun 30, 2022 | 31,274.00 |
| Mar 31, 2022 | 48,808.00 |
| Dec 31, 2021 | 60,237.00 |
| Sep 30, 2021 | 50,548.00 |
| Jun 30, 2021 | 46,650.00 |